-
1 Comment
Biotest Aktiengesellschaft is currently in a long term uptrend where the price is trading 13.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Biotest Aktiengesellschaft's total revenue rose by 14.8% to $143M since the same quarter in the previous year.
Its net income has increased by 122.2% to $400K since the same quarter in the previous year.
Finally, its free cash flow grew by 1090.5% to $21M since the same quarter in the previous year.
Based on the above factors, Biotest Aktiengesellschaft gets an overall score of 5/5.
| ISIN | DE0005227201 |
|---|---|
| CurrencyCode | EUR |
| Exchange | F |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 1B |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 33.8 |
| Beta | 0.29 |
| PE Ratio | None |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIO.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
